vs
碧迪（BDX）与Raymond James Financial（RJF）财务数据对比。点击上方公司名可切换其他公司
碧迪的季度营收约是Raymond James Financial的1.4倍（$5.3B vs $3.9B），Raymond James Financial净利率更高（14.1% vs 7.3%，领先6.8%），Raymond James Financial同比增速更快（13.0% vs -0.4%），过去两年碧迪的营收复合增速更高（2.0% vs 1.3%）
碧迪（Becton Dickinson）是美国跨国医疗科技企业，核心业务包括研发、生产及销售医用器械、仪器系统与试剂产品，同时在特定领域提供专业咨询及数据分析服务，业务覆盖全球多国，在全球医疗技术领域具备领先地位。
雷蒙德詹姆斯金融是美国跨国独立投资银行及金融服务机构，通过旗下子公司为个人、企业及市政主体提供多元金融服务，核心业务覆盖投资与财务规划、投资银行、资产管理等领域，总部位于美国佛罗里达州圣彼得堡。
BDX vs RJF — 直观对比
营收规模更大
BDX
是对方的1.4倍
$3.9B
营收增速更快
RJF
高出13.4%
-0.4%
净利率更高
RJF
高出6.8%
7.3%
两年增速更快
BDX
近两年复合增速
1.3%
损益表 — Q1 FY2026 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $5.3B | $3.9B |
| 净利润 | $382.0M | $544.0M |
| 毛利率 | 45.9% | — |
| 营业利润率 | 10.5% | — |
| 净利率 | 7.3% | 14.1% |
| 营收同比 | -0.4% | 13.0% |
| 净利润同比 | 24.0% | 10.0% |
| 每股收益（稀释后） | $1.34 | $2.83 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BDXRJF
| Q1 26 | — | $3.9B | ||
| Q4 25 | $5.3B | $4.2B | ||
| Q3 25 | $5.9B | $4.2B | ||
| Q2 25 | $5.5B | $3.8B | ||
| Q1 25 | $5.3B | $3.8B | ||
| Q4 24 | $5.2B | $4.0B | ||
| Q3 24 | $5.4B | $4.0B | ||
| Q2 24 | $5.0B | $3.8B |
净利润BDXRJF
| Q1 26 | — | $544.0M | ||
| Q4 25 | $382.0M | $563.0M | ||
| Q3 25 | $493.0M | $604.0M | ||
| Q2 25 | $574.0M | $436.0M | ||
| Q1 25 | $308.0M | $495.0M | ||
| Q4 24 | $303.0M | $600.0M | ||
| Q3 24 | $400.0M | $602.0M | ||
| Q2 24 | $487.0M | $492.0M |
毛利率BDXRJF
| Q1 26 | — | — | ||
| Q4 25 | 45.9% | — | ||
| Q3 25 | 47.5% | — | ||
| Q2 25 | 47.8% | — | ||
| Q1 25 | 42.8% | — | ||
| Q4 24 | 43.2% | — | ||
| Q3 24 | 45.7% | — | ||
| Q2 24 | 46.2% | — |
营业利润率BDXRJF
| Q1 26 | — | — | ||
| Q4 25 | 10.5% | — | ||
| Q3 25 | 11.8% | — | ||
| Q2 25 | 16.0% | 14.7% | ||
| Q1 25 | 10.4% | 17.5% | ||
| Q4 24 | 8.8% | 18.6% | ||
| Q3 24 | 11.4% | — | ||
| Q2 24 | 12.1% | 17.1% |
净利率BDXRJF
| Q1 26 | — | 14.1% | ||
| Q4 25 | 7.3% | 13.5% | ||
| Q3 25 | 8.4% | 14.4% | ||
| Q2 25 | 10.4% | 11.3% | ||
| Q1 25 | 5.8% | 12.9% | ||
| Q4 24 | 5.9% | 14.9% | ||
| Q3 24 | 7.4% | 15.0% | ||
| Q2 24 | 9.8% | 13.1% |
每股收益（稀释后）BDXRJF
| Q1 26 | — | $2.83 | ||
| Q4 25 | $1.34 | $2.79 | ||
| Q3 25 | $1.71 | $2.96 | ||
| Q2 25 | $2.00 | $2.12 | ||
| Q1 25 | $1.07 | $2.36 | ||
| Q4 24 | $1.04 | $2.86 | ||
| Q3 24 | $1.37 | $2.85 | ||
| Q2 24 | $1.68 | $2.31 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $740.0M | $5.4B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $25.3B | $52.0M |
| 总资产 | $54.8B | $91.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BDXRJF
| Q1 26 | — | $5.4B | ||
| Q4 25 | $740.0M | $9.9B | ||
| Q3 25 | $641.0M | $11.4B | ||
| Q2 25 | $735.0M | $9.2B | ||
| Q1 25 | $667.0M | $9.7B | ||
| Q4 24 | $711.0M | $10.0B | ||
| Q3 24 | $1.7B | $11.0B | ||
| Q2 24 | $4.5B | $9.1B |
股东权益BDXRJF
| Q1 26 | — | $52.0M | ||
| Q4 25 | $25.3B | $12.6B | ||
| Q3 25 | $25.4B | $12.5B | ||
| Q2 25 | $25.5B | $12.3B | ||
| Q1 25 | $25.2B | $12.2B | ||
| Q4 24 | $25.2B | $11.9B | ||
| Q3 24 | $25.9B | $11.7B | ||
| Q2 24 | $25.9B | $11.2B |
总资产BDXRJF
| Q1 26 | — | $91.9B | ||
| Q4 25 | $54.8B | $88.8B | ||
| Q3 25 | $55.3B | $88.2B | ||
| Q2 25 | $54.9B | $84.8B | ||
| Q1 25 | $54.5B | $83.1B | ||
| Q4 24 | $54.7B | $82.3B | ||
| Q3 24 | $57.3B | $83.0B | ||
| Q2 24 | $55.6B | $80.6B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $657.0M | — |
| 自由现金流经营现金流 - 资本支出 | $549.0M | — |
| 自由现金流率自由现金流/营收 | 10.5% | — |
| 资本支出强度资本支出/营收 | 2.1% | — |
| 现金转化率经营现金流/净利润 | 1.72× | — |
| 过去12个月自由现金流最近4个季度 | $2.6B | — |
8季度趋势，按日历期对齐
经营现金流BDXRJF
| Q1 26 | — | — | ||
| Q4 25 | $657.0M | $-10.0M | ||
| Q3 25 | $1.4B | $796.0M | ||
| Q2 25 | $1.2B | $691.0M | ||
| Q1 25 | $164.0M | $117.0M | ||
| Q4 24 | $693.0M | $830.0M | ||
| Q3 24 | $1.2B | $510.0M | ||
| Q2 24 | $1.3B | $711.0M |
自由现金流BDXRJF
| Q1 26 | — | — | ||
| Q4 25 | $549.0M | $-56.0M | ||
| Q3 25 | $1.0B | $752.0M | ||
| Q2 25 | $1.0B | $634.0M | ||
| Q1 25 | $35.0M | $71.0M | ||
| Q4 24 | $588.0M | $789.0M | ||
| Q3 24 | $882.0M | $460.0M | ||
| Q2 24 | $1.1B | $655.0M |
自由现金流率BDXRJF
| Q1 26 | — | — | ||
| Q4 25 | 10.5% | -1.3% | ||
| Q3 25 | 17.0% | 17.9% | ||
| Q2 25 | 19.0% | 16.5% | ||
| Q1 25 | 0.7% | 1.8% | ||
| Q4 24 | 11.4% | 19.6% | ||
| Q3 24 | 16.2% | 11.5% | ||
| Q2 24 | 22.4% | 17.4% |
资本支出强度BDXRJF
| Q1 26 | — | — | ||
| Q4 25 | 2.1% | 1.1% | ||
| Q3 25 | 6.0% | 1.1% | ||
| Q2 25 | 3.2% | 1.5% | ||
| Q1 25 | 2.4% | 1.2% | ||
| Q4 24 | 2.0% | 1.0% | ||
| Q3 24 | 5.4% | 1.2% | ||
| Q2 24 | 3.6% | 1.5% |
现金转化率BDXRJF
| Q1 26 | — | — | ||
| Q4 25 | 1.72× | -0.02× | ||
| Q3 25 | 2.75× | 1.32× | ||
| Q2 25 | 2.12× | 1.58× | ||
| Q1 25 | 0.53× | 0.24× | ||
| Q4 24 | 2.29× | 1.38× | ||
| Q3 24 | 2.94× | 0.85× | ||
| Q2 24 | 2.66× | 1.45× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BDX
| Other | $2.8B | 53% |
| Medication Management Solutions | $678.0M | 13% |
| Urologyand Critical Care | $339.0M | 6% |
| Surgery | $310.0M | 6% |
| Peripheral Intervention | $265.0M | 5% |
| Specimen Management | $245.0M | 5% |
| Advanced Patient Monitoring | $178.0M | 3% |
| Diagnostic Solutions | $176.0M | 3% |
| Bio Pharma Systems | $150.0M | 3% |
| Biosciences | $124.0M | 2% |
RJF
| Private Client Group | $2.8B | 73% |
| Bank | $486.0M | 13% |
| Capital Markets | $464.0M | 12% |
| Other | $99.0M | 3% |
